The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer: Validation using the mAb 12G4

Por Kersual, Nathalie, Garambois, Véronique, Chardès, Thierry, Pouget, Jean-Pierre, Salhi, Imed, Bascoul-Mollevi, Caroline, Bibeau, Frédéric, Busson, Muriel, Vié, Henri, Clémenceau, Béatrice, Behrens, Christian K, Estupina, Pauline, Pèlegrin, André, Navarro-Teulon, Isabelle
Publicado no MAbs (2014)

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells

Por Estupina, Pauline, Fontayne, Alexandre, Barret, Jean-Marc, Kersual, Nathalie, Dubreuil, Olivier, Le Blay, Marion, Pichard, Alexandre, Jarlier, Marta, Pugnière, Martine, Chauvin, Maëva, Chardès, Thierry, Pouget, Jean-Pierre, Deshayes, Emmanuel, Rossignol, Alexis, Abache, Toufik, de Romeuf, Christophe, Terrier, Aurélie, Verhaeghe, Lucie, Gaucher, Christine, Prost, Jean-François, Pèlegrin, André, Navarro-Teulon, Isabelle
Publicado no Oncotarget (2017)